NEW YORK (GenomeWeb) – Ventana today said that it is collaborating with MedImmune to develop a companion diagnostic for a drug MedImmune is developing for non-small cell lung cancer.

The companion diagnostic will be an immunohistochemistry assay that aims to identify patients who express programmed cell death ligand 1. MedImmune is developing an anti-PD-L1 therapy dubbed MEDI4736, which is currently in clinical studies. The drug firm will use the Ventana assay in that study.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Jun
14
Sponsored by
Sophia Genetics

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.